Scientists are reporting a potentially groundbreaking development in the battle against pancreatic cancer, one of the deadliest forms of the disease. Recent clinical trials have revealed that combining the drug daraxonrasib with traditional chemotherapy medications can lead to dramatically shrunken tumors, with some patients showing no detectable signs of cancer following treatment. This finding is generating considerable excitement among medical researchers and oncologists worldwide.
"This is the closest to cure. We’ve never seen such a thing." Dr. Wungki Park, Oncologist.
Pancreatic cancer has long been known for its aggressive nature and resistance to conventional treatments, maintaining an overall five-year survival rate of approximately 13.7 percent. The disease has claimed the lives of numerous public figures, underscoring the urgent need for more effective therapies. Daraxonrasib, an oral medication sold under the name Rasonque, received approval in August 2026 for its ability to target the mutated KRAS protein, which drives uncontrolled cancer cell growth. Previous research had shown the drug alone could significantly increase median survival for patients.
The latest findings, presented by oncologist Dr. Wungki Park, focused on patients with Stage 4 pancreatic cancer, an advanced stage where the disease has spread to other parts of the body. Participants in the clinical trial received daraxonrasib in conjunction with two established chemotherapy medications, gemcitabine and nab-paclitaxel. The results indicated substantial improvements in disease control compared to previous benchmarks.
According to the trial data, approximately nine out of ten patients experienced either shrinkage or stabilization of their tumors during the treatment period. Even more encouraging, roughly three out of five participants achieved substantial tumor shrinkage or, in some cases, complete disappearance of detectable cancer. Specifically, researchers reported that 8.2% of patients, equating to about one in twelve, had no detectable cancer at the conclusion of the study. Furthermore, more than 76% of participants survived beyond one year while receiving this combination treatment.
Dr. Park described the results in emphatic terms, stating, "This is the closest to cure. We’ve never seen such a thing." He further characterized the development as a "massive, massive breakthrough" in the ongoing fight against pancreatic cancer. The median follow-up period for the clinical trial spanned 18.3 months, allowing researchers to assess the durability of these improvements beyond immediate treatment. The median progression-free survival also exceeded one year, suggesting many patients experienced extended periods without their cancer worsening.
Dr. Nicholas Hornstein, a medical oncologist at Northwell’s Lenox Hill Hospital, explained daraxonrasib's mechanism of action by likening the malfunctioning KRAS protein to a "stuck accelerator" continuously prompting cancer cells to multiply. By interfering with this process, daraxonrasib aims to slow or halt tumor growth. The combination therapy offers a new avenue of hope against a disease that has historically proven resilient to various treatments, including chemotherapy, radiation, immunotherapy, and other targeted medications.
Despite the significant promise, the new medication is not without its challenges and side effects. Former Republican Sen. Ben Sasse, who was diagnosed with Stage 4 pancreatic cancer in December 2025, publicly shared his experience with daraxonrasib. As reported by the New York Post, Sasse noted the drug’s severity, stating, "I take it orally, but it’s a nasty drug." Clinical trial data supports this, indicating that dermatologic toxicity, or severe skin-related complications, occurred in approximately 86 percent of patients, with 10 percent experiencing severe reactions. While Sasse survived significantly longer than his initial prognosis, he reported in September that some of his tumors were developing resistance to the treatment, highlighting both the benefits and limitations of current therapies.
Researchers are now focused on further evaluating whether the combination of daraxonrasib and chemotherapy can provide even stronger and more lasting results for individuals with advanced pancreatic cancer. Dr. Alan Sandler, chief development officer of Revolution Medicines, underscored the critical need for improved options for patients facing metastatic pancreatic cancer, noting that current chemotherapy regimens offer limited benefits for many. While the ability to make previously detectable tumors disappear does not equate to a permanent cure, these findings represent a potentially crucial step forward. For patients confronting one of medicine’s most formidable cancers, the research offers renewed optimism for treatments capable of extending survival and achieving deeper responses than previously thought possible.